Estradiol Patch Shortages Persisted Through September
Rising demand for hormone therapy following FDA labeling changes caused supply constraints for pharmacies across the U.S.
Updated on Sept. 18, 2026 in Women’s Health
Live Poll
Are you confident in the availability of your prescription medications when you need them?
As of September 2026, pharmacies across the United States reported ongoing supply shortages for various estradiol transdermal products. The scarcity follows a 162% surge in prescriptions for the patches over the past two years.
Why it matters
Demand spiked after the FDA removed long-standing black box warnings from menopause hormone therapy labels in November 2025. This regulatory shift prompted more patients to seek treatment, outpacing current manufacturing capacity.
The American Society of Health-System Pharmacists confirms shortages across multiple products, despite FDA data indicating that overall supply has nearly doubled over the last year. Manufacturers currently producing these patches include Amneal, Sandoz, Noven, Bayer, Zydus, and Viatris.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating medications and overseeing safety labeling for hormone therapies.
HHS
The Department of Health and Human Services is the federal executive branch agency that has initiated meetings with manufacturers to address supply shortages.
Bayer
Bayer is a multinational pharmaceutical company that manufactures estradiol patch products and manages distribution to the U.S. market.
American Society of Health-System Pharmacists
This professional organization tracks medication availability and maintains the official lists identifying product shortages for the healthcare industry.
The details
Manufacturers are working to address the shortfall by adding production shifts, expanding capacity, and increasing batch sizes. While the FDA is conducting expedited reviews to speed up supply, Bayer has noted that temporary constraints on one Climara dose will likely persist into early 2027.
Timeline
November 2025: The FDA removed black box warnings from hormone therapy labels.
February 2026: The FDA approved the first batch of updated product labels.
September 3, 2026: The FDA acknowledged reports of patient difficulty accessing patches.
The Big Picture
This shift represents a significant reversal of the regulatory environment established by the 2002 Women's Health Initiative trial, which triggered decades of restrictive black box warnings on hormone therapy products. The current shortage follows the subsequent removal of those warnings, which has fundamentally changed the clinical landscape for menopause treatment.
Patients may experience continued difficulty filling prescriptions at local pharmacies as supply constraints remain for certain dosages. Individuals should consult their healthcare providers to discuss alternative formulations or potential timing for medication availability.
The takeaway
The surge in demand for estradiol patches demonstrates how quickly regulatory changes can alter the availability of essential medications. Patients are encouraged to maintain open communication with their pharmacists to navigate ongoing, intermittent supply challenges.
Further reading
For more information on current treatment options, visit the Women’s Health section.
Live Poll
Are you confident in the availability of your prescription medications when you need them?
